Published in JAMA on January 09, 2008
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Taxonomizing, sizing, and overcoming the incidentalome. Genet Med (2012) 3.82
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Genetic susceptibility to breast cancer. Mol Oncol (2010) 2.52
Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA (2009) 2.42
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med (2010) 2.17
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet (2008) 1.96
Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst (2010) 1.91
Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet (2013) 1.91
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol (2010) 1.85
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol (2011) 1.79
The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med (2014) 1.68
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Incorporating model uncertainty in detecting rare variants: the Bayesian risk index. Genet Epidemiol (2011) 1.41
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat (2010) 1.40
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol (2012) 1.35
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2010) 1.15
Performance of BRCA1/2 mutation prediction models in Asian Americans. J Clin Oncol (2008) 1.14
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol (2012) 1.13
Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med (2010) 1.13
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat (2010) 1.11
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat (2010) 1.10
Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol (2014) 1.08
Breast cancer risks and risk prediction models. Breast Care (Basel) (2015) 1.07
Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling. Genet Epidemiol (2011) 1.04
Incorporating prior biologic information for high-dimensional rare variant association studies. Hum Hered (2013) 0.98
Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res (2008) 0.98
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn (2012) 0.97
A genomewide screen for suppressors of Alu-mediated rearrangements reveals a role for PIF1. PLoS One (2012) 0.96
Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep (2011) 0.95
Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2008) 0.94
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. BMC Med Genomics (2011) 0.94
Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study. Br J Cancer (2008) 0.93
Solid tumor second primary neoplasms: who is at risk, what can we do? Semin Oncol (2013) 0.92
Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1. Mutat Res (2008) 0.91
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. Eur J Cancer (2013) 0.90
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Hum Mol Genet (2011) 0.89
Multicenter breast cancer collaborative registry. Cancer Inform (2011) 0.88
A frailty-model-based approach to estimating the age-dependent penetrance function of candidate genes using population-based case-control study designs: an application to data on the BRCA1 gene. Biometrics (2009) 0.88
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Res (2012) 0.88
Map making in the 21st century: charting breast cancer susceptibility pathways in rodent models. J Mammary Gland Biol Neoplasia (2011) 0.85
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). Breast Cancer Res (2012) 0.85
Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol (2016) 0.85
A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history. Fam Cancer (2011) 0.83
Using Population Genetics to Interrogate the Monogenic Nephrotic Syndrome Diagnosis in a Case Cohort. J Am Soc Nephrol (2015) 0.82
Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study. Cancer Causes Control (2010) 0.82
Frailty Models for Familial Risk with Application to Breast Cancer. J Am Stat Assoc (2013) 0.82
Two-phase and family-based designs for next-generation sequencing studies. Front Genet (2013) 0.82
The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2009) 0.82
Environment and genetics: Making sense of the noise. Nature (2012) 0.81
Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. Fam Cancer (2012) 0.81
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2014) 0.80
Risk-association of CYP11A1 polymorphisms and breast cancer among Han Chinese women in Southern China. Int J Mol Sci (2012) 0.80
Metabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin? Curr Breast Cancer Rep (2011) 0.79
Management of the asymptomatic BRCA mutation carrier. Appl Clin Genet (2010) 0.78
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2009) 0.78
Evidence that BRCA1- or BRCA2-associated cancers are not inevitable. Mol Med (2012) 0.78
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2012) 0.78
Structure-activity relationship of the peptide binding-motif mediating the BRCA2:RAD51 protein-protein interaction. FEBS Lett (2016) 0.77
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Res Treat (2009) 0.77
Opportunities and Challenges of Genotyping Patients With Nephrotic Syndrome in the Genomic Era. Semin Nephrol (2015) 0.77
Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. Breast Cancer Res Treat (2015) 0.77
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat (2016) 0.75
A Bayesian Hierarchical Model for Relating Multiple SNPs within Multiple Genes to Disease Risk. Int J Genomics (2013) 0.75
Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer. Biomark Cancer (2015) 0.75
High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series. Hered Cancer Clin Pract (2010) 0.75
Polymorphic repeat length in the AIB1 gene and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis of observational studies. PLoS One (2013) 0.75
Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer. Cancer Med (2016) 0.75
Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer. Curr Breast Cancer Rep (2011) 0.75
The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2012) 0.75
An ovarian mass after breast cancer: Metachronous carcinoma or metastasis? A case report. Int J Surg Case Rep (2016) 0.75
Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers. J Clin Oncol (2015) 0.75
Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. Hereditary Genet (2012) 0.75
Hereditary gynaecologic cancers in Nepal: a proposed model of care to serve high risk populations in developing countries. Hered Cancer Clin Pract (2017) 0.75
Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. Fam Cancer (2015) 0.75
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst (2002) 7.64
Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol (2007) 7.46
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst (2006) 6.73
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer (1997) 4.47
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer (2000) 4.37
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet (1998) 3.61
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev (1999) 3.29
Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst (1999) 2.99
Validation of family history data in cancer family registries. Am J Prev Med (2003) 2.80
Risk models for familial ovarian and breast cancer. Genet Epidemiol (2000) 2.75
Models of genetic susceptibility to breast cancer. Oncogene (2006) 2.69
Can familial aggregation of disease be explained by familial aggregation of environmental risk factors? Am J Epidemiol (1988) 2.35
Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst (2006) 2.25
Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev (2002) 2.10
Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res (2004) 2.03
Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res (1991) 1.89
Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res (2006) 1.77
ATM and breast cancer susceptibility. Oncogene (2006) 1.68
A marginal likelihood approach for estimating penetrance from kin-cohort designs. Biometrics (2001) 1.49
Accuracy of family history of cancer obtained through interviews with relatives of patients with childhood sarcoma. J Clin Epidemiol (1994) 1.49
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer (2005) 1.48
Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat (2003) 1.33
Why are the majority of hereditary cases of early-onset breast cancer sporadic? A simulation study. Cancer Epidemiol Biomarkers Prev (2000) 1.07
Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene. Genet Epidemiol (2003) 1.03
Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2006) 1.03
Polygenic inherited predisposition to breast cancer. Cold Spring Harb Symp Quant Biol (2005) 1.02
Ascertainment bias in rate ratio estimation from case-sibling control studies of variable age-at-onset diseases. Biometrics (1999) 0.95
Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst (2003) 0.82
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet (2009) 16.53
Body-mass index and mortality among 1.46 million white adults. N Engl J Med (2010) 13.34
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA (2007) 7.93
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science (2013) 6.98
Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med (2003) 6.47
Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect (2004) 6.43
BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol (2002) 6.35
Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol (2002) 5.81
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
Oral contraceptives and the risk of breast cancer. N Engl J Med (2002) 4.85
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA (2010) 4.71
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control (2008) 4.56
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res (2004) 4.54
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med (2013) 4.36
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered (2003) 4.34
Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology (2005) 4.31
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res (2006) 4.28
Use of mobile phones and risk of brain tumours: update of Danish cohort study. BMJ (2011) 4.08
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA (2003) 4.01
Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell (2006) 4.01
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA (2005) 3.99
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control (2002) 3.81
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Recent developments in genomewide association scans: a workshop summary and review. Am J Hum Genet (2005) 3.76
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73
Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. Am J Epidemiol (2010) 3.64
Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res (2006) 3.62
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol (2009) 3.58
Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol (2007) 3.52
Cancer risk among statin users: a population-based cohort study. Int J Cancer (2005) 3.50
Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst (2003) 3.44
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med (2012) 3.44
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Optimal two-stage genotyping designs for genome-wide association scans. Genet Epidemiol (2006) 3.41
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
Nitrate in public water supplies and the risk of colon and rectum cancers. Epidemiology (2003) 3.39
Betting odds and genetic associations. J Natl Cancer Inst (2004) 3.39
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer (2003) 3.25
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Clinically relevant changes in family history of cancer over time. JAMA (2011) 3.18
Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev (2003) 3.11
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
The landscape of recombination in African Americans. Nature (2011) 3.06
Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst (2013) 3.06
Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res (2006) 3.06
Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol (2003) 3.05
Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA (2003) 3.04
Reliability of reporting on life-style and agricultural factors by a sample of participants in the Agricultural Health Study from Iowa. Epidemiology (2002) 3.00
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Physical activity levels among breast cancer survivors. Med Sci Sports Exerc (2004) 2.88
Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol (2008) 2.85
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol (2010) 2.81
Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res (2004) 2.80
Validation of family history data in cancer family registries. Am J Prev Med (2003) 2.80
Natural history of stage I non-small cell lung cancer: implications for early detection. Chest (2007) 2.78
A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health A (2006) 2.78
Long-term exposure to constituents of fine particulate air pollution and mortality: results from the California Teachers Study. Environ Health Perspect (2009) 2.72
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70
Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays. Genome Biol (2008) 2.67
Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol (2002) 2.67
Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios. BMC Bioinformatics (2008) 2.66
Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol (2003) 2.65
Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst (2009) 2.64
Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol (2002) 2.63
Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. J Natl Cancer Inst (2004) 2.62
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62